FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045183903> ?p ?o ?g. }

• W2045183903 endingPage "761" @default.
• W2045183903 startingPage "752" @default.
• W2045183903 abstract "Medical records (2005-2009) of a feline-only practice were searched for cats with degenerative joint disease (DJD) treated using meloxicam. DJD was diagnosed by the presence of at least two of the following: (i) altered mobility (observed by the owner), (ii) abnormal physical findings, (iii) characteristic radiographic changes. The primary study cohort consisted of cats older than 7 years that had received meloxicam for variable intervals in excess of 6 months, and for which complete records were available. These cats were subdivided according to whether detectable chronic kidney disease (CKD) was present ('renal group'), or not ('non-renal group'), and, for the 'renal group', according to the cat's IRIS category. Serum biochemistry, urinalysis (including urine specific gravity [USG]), body mass and condition score were monitored regularly. Progression of CKD in the 'renal group' and 'non-renal group' of cats was compared to two groups of age- and IRIS-matched control cats not receiving meloxicam (from the same clinic, over the same time period). The study was thus a case-control design, with two study groups. Thirty-eight cats with DJD receiving long-term meloxicam therapy met the inclusion criteria. Of these, 22 cats had stable CKD at the start of treatment (stage 1, eight cats; stage 2, 13 cats; stage 3, one cat). No cats initially had an elevated urinary protein to creatinine ratio. The remaining 16 cats initially had normal renal analytes and adequately concentrated urine. The median age of the 'renal' and 'non-renal' meloxicam groups was 15.5 and 13.4 years, respectively. The median treatment duration was 467 days in the 'renal group' and 327 days in the 'non-renal group'. After titration (to the lowest effective dose), the median maintenance dose was 0.02 mg/kg/day in both groups (range 0.015-0.033 mg/kg/day). There was no difference in sequential serum creatinine concentration or USG measurements between the 'non-renal group' treated with meloxicam compared to control cats not treated with meloxicam. There was less progression of renal disease in the 'renal group' treated with meloxicam compared to the age- and IRIS-matched cats with CKD not given meloxicam. These results suggest that a long-term maintenance dose of 0.02 mg/kg of meloxicam can be safely administered to cats older than 7 years even if they have CKD, provided their overall clinical status is stable. Long-term meloxicam therapy may slow the progression of renal disease in some cats suffering from both CKD and DJD. Prospective studies are required to confirm these findings." @default.
• W2045183903 created "2016-06-24" @default.
• W2045183903 creator A5000592280 @default.
• W2045183903 creator A5042365249 @default.
• W2045183903 creator A5050978023 @default.
• W2045183903 creator A5054885182 @default.
• W2045183903 creator A5067362397 @default.
• W2045183903 creator A5075356276 @default.
• W2045183903 date "2011-10-01" @default.
• W2045183903 modified "2023-10-05" @default.
• W2045183903 title "Retrospective Case—Control Study of the Effects of Long-Term Dosing with Meloxicam on Renal Function in Aged Cats with Degenerative Joint Disease" @default.
• W2045183903 cites W1966247969 @default.
• W2045183903 cites W1967897673 @default.
• W2045183903 cites W1994977169 @default.
• W2045183903 cites W2011605357 @default.
• W2045183903 cites W2012230387 @default.
• W2045183903 cites W2034831445 @default.
• W2045183903 cites W2038876111 @default.
• W2045183903 cites W2049727846 @default.
• W2045183903 cites W2052940138 @default.
• W2045183903 cites W2052997652 @default.
• W2045183903 cites W2075887145 @default.
• W2045183903 cites W2078312942 @default.
• W2045183903 cites W2086697102 @default.
• W2045183903 cites W2092606556 @default.
• W2045183903 cites W2097248318 @default.
• W2045183903 cites W2104476071 @default.
• W2045183903 cites W2112235937 @default.
• W2045183903 cites W2121661738 @default.
• W2045183903 cites W2122317595 @default.
• W2045183903 cites W2125895407 @default.
• W2045183903 cites W2129119242 @default.
• W2045183903 cites W2132278120 @default.
• W2045183903 cites W2148897023 @default.
• W2045183903 cites W2150076351 @default.
• W2045183903 cites W2163070765 @default.
• W2045183903 cites W2170889992 @default.
• W2045183903 cites W2317175410 @default.
• W2045183903 cites W2502670554 @default.
• W2045183903 cites W4251066163 @default.
• W2045183903 cites W4251919176 @default.
• W2045183903 doi "https://doi.org/10.1016/j.jfms.2011.06.008" @default.
• W2045183903 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21906984" @default.
• W2045183903 hasPublicationYear "2011" @default.
• W2045183903 type Work @default.
• W2045183903 sameAs 2045183903 @default.
• W2045183903 citedByCount "84" @default.
• W2045183903 countsByYear W20451839032012 @default.
• W2045183903 countsByYear W20451839032013 @default.
• W2045183903 countsByYear W20451839032014 @default.
• W2045183903 countsByYear W20451839032015 @default.
• W2045183903 countsByYear W20451839032016 @default.
• W2045183903 countsByYear W20451839032017 @default.
• W2045183903 countsByYear W20451839032018 @default.
• W2045183903 countsByYear W20451839032019 @default.
• W2045183903 countsByYear W20451839032020 @default.
• W2045183903 countsByYear W20451839032021 @default.
• W2045183903 countsByYear W20451839032022 @default.
• W2045183903 countsByYear W20451839032023 @default.
• W2045183903 crossrefType "journal-article" @default.
• W2045183903 hasAuthorship W2045183903A5000592280 @default.
• W2045183903 hasAuthorship W2045183903A5042365249 @default.
• W2045183903 hasAuthorship W2045183903A5050978023 @default.
• W2045183903 hasAuthorship W2045183903A5054885182 @default.
• W2045183903 hasAuthorship W2045183903A5067362397 @default.
• W2045183903 hasAuthorship W2045183903A5075356276 @default.
• W2045183903 hasBestOaLocation W20451839031 @default.
• W2045183903 hasConcept C126322002 @default.
• W2045183903 hasConcept C126894567 @default.
• W2045183903 hasConcept C159641895 @default.
• W2045183903 hasConcept C167135981 @default.
• W2045183903 hasConcept C2778653478 @default.
• W2045183903 hasConcept C2779225474 @default.
• W2045183903 hasConcept C2779751750 @default.
• W2045183903 hasConcept C2779904517 @default.
• W2045183903 hasConcept C2780306776 @default.
• W2045183903 hasConcept C71924100 @default.
• W2045183903 hasConcept C77411442 @default.
• W2045183903 hasConceptScore W2045183903C126322002 @default.
• W2045183903 hasConceptScore W2045183903C126894567 @default.
• W2045183903 hasConceptScore W2045183903C159641895 @default.
• W2045183903 hasConceptScore W2045183903C167135981 @default.
• W2045183903 hasConceptScore W2045183903C2778653478 @default.
• W2045183903 hasConceptScore W2045183903C2779225474 @default.
• W2045183903 hasConceptScore W2045183903C2779751750 @default.
• W2045183903 hasConceptScore W2045183903C2779904517 @default.
• W2045183903 hasConceptScore W2045183903C2780306776 @default.
• W2045183903 hasConceptScore W2045183903C71924100 @default.
• W2045183903 hasConceptScore W2045183903C77411442 @default.
• W2045183903 hasIssue "10" @default.
• W2045183903 hasLocation W20451839031 @default.
• W2045183903 hasLocation W20451839032 @default.
• W2045183903 hasOpenAccess W2045183903 @default.
• W2045183903 hasPrimaryLocation W20451839031 @default.
• W2045183903 hasRelatedWork W2046899919 @default.
• W2045183903 hasRelatedWork W2124543160 @default.
• W2045183903 hasRelatedWork W2140445493 @default.
• W2045183903 hasRelatedWork W2403253581 @default.

• next